Osteoporosis associated with excess glucocorticoids

Endocrinology and Metabolism Clinics of North America

Volumn 34, Issue 2, 2005, Pages 341-356

  Shaker, Joseph L ^a   Lukert, Barbara P ^b  

^a UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ANABOLIC AGENT; BECLOMETASONE; BISPHOSPHONIC ACID DERIVATIVE; BRONCHODILATING AGENT; CALCITRIOL; CALCIUM; CHLOROTRIANISENE; CORTICOSTEROID; ESTRADIOL; ETIDRONIC ACID; FLUORIDE SODIUM; FLUTICASONE PROPIONATE; GLUCOCORTICOID; IBANDRONIC ACID; NANDROLONE; NORETHISTERONE; PAMIDRONIC ACID; PARATHYROID HORMONE; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; STRONTIUM RANELATE; TESTOSTERONE; THIAZIDE DIURETIC AGENT; TRIAMCINOLONE; VITAMIN D;

ADRENAL CORTEX ADENOMA; ALCOHOL CONSUMPTION; AMENORRHEA; ANDROGEN DEFICIENCY; ARTERITIS; ASTHMA; AVASCULAR NECROSIS; BONE DEFECT; BONE DENSITY; BONE GROWTH; BONE MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; CUSHING SYNDROME; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG RESPONSE; FRAGILITY FRACTURE; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERCORTISOLISM; LIFESTYLE; LONG TERM CARE; META ANALYSIS; OSTEOLYSIS; PATHOGENESIS; PHYSIOTHERAPY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RIB FRACTURE; RISK ASSESSMENT; SMOKING CESSATION; TREATMENT INDICATION; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

EID: 18044398760     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2005.01.014     Document Type: Review

References (102)

1. H. Cushing The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism) Bull Johns Hopkins Hosp 1 3 1932 137 195
2. R.B. Welbourn, D.A.D. Montgomery, and T.L. Kennedy The natural history of treated Cushing's syndrome Br J Surg 58 1 1971 1 16
3. S.F. Hodgson Corticosteroid-induced osteoporosis Endocrinol Metab Clin North Am 19 1 1990 95 111
4. C. Di Somma, R. Pivonello, and S. Loche Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease Clin Endocrinol 56 2002 153 158
5. I. Chiodini, V. Carnevale, and M. Torlontano Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing's syndrome J Clin Endocrinol Metab 83 1998 1863 1867
6. P. Vestergaard, J. Lindholm, and J.O.L. Jorgensen Increased risk of osteoporotic fractures in patients with Cushing's syndrome Eur J Endocrinol 146 2002 51 56
7. M. Kleerekoper, S.D. Rao, and B. Frame Occult Cushing's syndrome presenting with osteoporosis Henry Ford Hosp Med J 28 1980 132 136
8. N. Ohmori, K. Nomura, and K. Ohmori Osteoporosis is more prevalent in adrenal than in pituitary Cushing's syndrome Endocr J 50 2003 1 7
9. M. Minetto, G. Reimondo, and G. Osella Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome Osteoporos Int 15 2004 855 861
10. G. Osella, M. Terzolo, and G. Reimondo Serum markers of bone and collagen turnover in patients with Cushing's syndrome and in subjects with adrenal incidentalomas J Clin Endocrinol Metab 82 1997 3303 3307
11. M. Torlontano, I. Chiodini, and M. Pileri Altered bone mass and turnover in female patients with adrenal incidentaloma: the effect of subclinical hypercortisolism J Clin Endocrinol Metab 84 1999 2381 2385
12. D. Hadjidakis, S. Tsagarakis, and C. Roboti Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas? Clin Endocrinol 58 2003 72 77
13. I. Chiodini, L. Tauchmanova, and M. Torlontano Bone involvement in eugonadal male patients with adrenal incidentaloma and subclinical hypercortisolism J Clin Endocrinol Metab 87 2002 5491 5494
14. L. Graves, and B.P. Lukert Glucocorticoid-induced osteoporosis Clinical Reviews in Bone and Mineral Metabolism 2 2 2004 79 90
15. L.D. Carbonare, M.E. Arlot, and A.P.M. Chavassieux Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis J Bone Miner Res 16 2001 97 103
16. R.F. Laan, W.C. Buijs, and L.J. van Erning Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content Calcif Tissue Int 52 1993 5 9
17. R.F.J.M. Laan, P.L.C.M. van Riel, and L.B.A. van de Putte Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis Ann Intern Med 119 1993 963 968
18. A.D. Adinoff, and J.R. Hollister Steroid-induced fractures and bone loss in patients with asthma N Engl J Med 309 1983 265 268
19. T.P. Van Staa, H.G.M. Leufkens, and L. Abenhaim Use of oral corticosteroids and risk of fractures J Bone Miner Res 15 2000 993 1000
20. J.A. Kanis, H. Johansson, and A. Oden A meta-analysis of prior corticosteroid use and fracture risk J Bone Miner Res 19 2004 893 899
21. T.P. Van Staa, C. Cooper, and H.G.M. Leufkens Children and the risk of fractures caused by oral corticosteroids J Bone Miner Res 18 2003 913 918
22. S. Cohen, R.M. Levy, and M. Keller Risedronate therapy prevents corticosteroid-induced bone loss Arthritis Rheum 42 11 1999 2309 2318
23. M. Luengo, C. Picado, and L. Del Rio Vertebral fractures in steroid-dependent asthma and involutional osteoporosis: a comparative study Thorax 46 1991 803 806
24. P.L. Selby, J.P. Halsey, and K.R.H. Adams Corticosteroids do not alter the threshold for vertebral fracture J Bone Miner Res 15 2000 952 956
25. T.P. Van Staa, R.F. Laan, and I.P. Barton Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy Arthritis Rheum 48 2003 3224 3229
26. J.R. Curtis, J. Allison, and A. Becker Screening and treatment of glucocorticoid induced osteoporosis among 6517 adults [abstract] J Bone Miner Res 19 Suppl 1 2004 1114
27. E.M. Pouw, M.F. Prummel, and H. Oosting Beclomethasone inhalation decreases serum osteocalcin concentrations BMJ 302 1991 627 628
28. H. Poulijoki, K. Liippo, and J. Herrala Inhaled beclomethasone decreases serum osteocalcin in postmenopausal asthmatic women Bone 13 1992 285 288
29. E.M.C. Lau, M. Li, and J. Woo Bone mineral density and body composition in patients with airflow obstruction-the role of inhaled steroid therapy, disease and lifestyle Clin Exp Allergy 28 1998 1066 1071
30. C.A. Wong, L.J. Walsh, and C.J.P. Smith Inhaled corticosteroid use and bone mineral density in patients with asthma Lancet 355 2000 1399 1403
31. K. Fujita, S. Kasayama, and J. Hashimoto Inhaled corticosteroids reduce bone mineral density in early postmenopausal but not premenopausal asthmatic women J Bone Miner Res 16 2001 782 787
32. E. Israel, T.R. Banerjee, and G.M. Fitzmaurice Effects of inhaled glucocorticoids on bone density in premenopausal women N Engl J Med 345 2001 941 947
33. J.P. Kemp, S. Osur, and S.B. Shrewsbury Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial Mayo Clin Proc 79 2004 458 466
34. T.P. Van Staa, H.G.M. Leufkens, and C. Cooper Use of inhaled corticosteroids and risk of fractures J Bone Miner Res 16 2001 581 588
35. M.R. MacAdams, R.H. White, and B.E. Chipps Reduction of serum testosterone levels during chronic glucocorticoid therapy Ann Intern Med 104 1986 648 651
36. G. Hampson, N. Bhargava, and J. Cheung Low circulating estradiol and adrenal androgens concentrations in men on glucocorticoids. a potential contributory factor in steroid-induced osteoporosis Metabolism 51 2002 1458 1462
37. L.C. Hofbauer, F. Gori, and L. Riggs Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis Endocrinology 140 1999 4382 4389
38. H.A. Morris, A.G. Need, and P.D. O'Loughlin Malabsorption of calcium in corticosteroid-induced osteoporosis Calcif Tissue Int 46 1990 305 308
39. I.R. Reid, and H.K. Ibbertson Evidence for decreased tubular reabsorption of calcium in glucocorticoid-treated asthmatics Horm Res 27 1987 200 204
40. M.E. Rubin, and J.P. Bilezikian The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence J Clin Endocrinol Metab 87 9 2002 4033 4041
41. R.S. Weinstein, R.L. Jilka, and A.M. Parfitt Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone J Clin Invest 102 2 1998 274 282
42. A. Dovio, L. Perazzolo, and G. Osella Immediate fall of bone formation and transient increase in bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis J Clin Endocrinol Metab 89 2004 4923 4928
43. E. Canalis, and A.M. Delany Mechanisms of glucocorticoid action in bone Ann N Y Acad Sci 966 2002 73 81
44. M. Centrella, T.L. McCarthy, and E. Canalis Glucocorticoid regulation of transforming growth factor β1 activity and binding in osteoblast-enriched cultures from fetal rat bone Mol Cell Biol 11 1991 4490 4496
45. K. Ohnaka, H. Taniguchi, and H. Kawate Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis Biochem Biophys Res Com 318 2004 259 264
46. M.S. Cooper, E.H. Rabbitt, and P.E. Goddard Osteoblastic 11β-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure J Bone Miner Res 17 6 2002 979 986
47. M.S. Cooper, I. Bujalska, and E.H. Rabbit Modulation of 11 beta-hydroxysteroid dehydrogenase isoenzymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation J Bone Miner Res 17 2001 1037 1044
48. N.A. Pocock, J.A. Eisman, and C.R. Dunstan Recovery from steroid-induced osteoporosis Ann Intern Med 107 1987 319 323
49. E.G. Lufkin, H.W. Wahner, and E.J. Bergstralh Reversibility of steroid-induced osteoporosis Am J Med 85 1988 887 888
50. P.J. Manning, M.C. Evans, and I.R. Reid Normal bone mineral density following cure of Cushing's syndrome Clin Endocrinol 36 1992 229 234
51. A.R. Hermus, A.G. Smals, and L.M. Swinkels Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome J Clin Endocrinol Metab 80 1995 2859 2865
52. H. Dobnig, V. Stepan, and G. Leb Recovery from severe osteoporosis following cure from ectopic ACTH syndrome caused by an appendix carcinoid J Intern Med 239 1996 365 369
53. C. Di Somma, R. Pivonello, and S. Loche Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study Clin Endocrinol 58 2003 302 308
54. K.L. Gebhard, and H.I. Mailbach Relationship between systemic corticosteroids and osteonecrosis American Journal of Clinical Dermatology 2 6 2001 377 388
55. N.E. Lane, and B. Lukert The science and therapy of glucocorticoid- induced bone loss Endocrinol Metab Clin North Am 27 2 1998 465 483
56. D.T. Felson, and J.J. Anderson A cross-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone Lancet 1 8538 1987 902 906
57. H.J. Mankin Nontraumatic necrosis of bone (osteonecrosis) N Engl J Med 326 22 1992 1473 1479
58. R.S. Weinstein, R.W. Nicholas, and S. Manolagas Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip J Clin Endocrinol Metab 85 2000 2907 2912
59. J.W. Pritchett Statin therapy decreases the risk of osteonecrosis in patients receiving steroids Clinical Orthopedics and Related Research 1 386 2001 173 178
60. J.R. Lieberman, D.J. Berry, and M.A. Mont Osteonecrosis of the hip: management in the twenty-first century J Bone Joint Surg 84-A 5 2002 834 853
61. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis Arthritis Rheum 44 2001 1496 1503
62. S. Amin, P. LaValley, and R. Simms The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach Arthritis Rheum 42 8 1999 1740 1751
63. L.M. Buckley, E.S. Leib, and K.S. Cartularo Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis Ann Intern Med 125 1996 961 968
64. J.D. Adachi, W.G. Bensen, and F. Bianchi Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3-year follow-up J Rheumatol 23 1996 995 1000
65. S. Amin, M.P. Lavalley, and R.W. Simms The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression J Bone Miner Res 17 8 2002 1512 1526
66. P. Sambrook, J. Birmingham, and P. Kelly Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin N Engl J Med 328 1993 1747 1752
67. J. Gram, P. Junker, and H.K. Nielsen Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men Bone 23 1998 297 302
68. J.Y. Reginster, D. Kuntz, and W. Verdickt Prophylactic use of alfacalcidiol in corticosteroid-induced osteoporosis Osteoporos Int 9 1999 75 81
69. P.N. Sambrook, M. Kotowicz, and P. Nash Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium J Bone Miner Res 18 2003 919 924
70. A.Z. LaCroix, S.M. Ott, and L. Ichikawa Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults; a randomized, double-blind, placebo-controlled trial Ann Intern Med 133 2000 516 526
71. G. Jones, T. Nguyen, and P.N. Sambrook Thiazide diuretics and fractures: can meta-analysis help? J Bone Miner Res 10 1995 106 111
72. I.R. Reid, D.J. Wattie, and M.C. Evans Testosterone therapy in glucocorticoid-treated men Arch Intern Med 156 1996 1173 1177
73. B.A.L. Crawford, P.Y. Liu, and M.T. Kean Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment J Clin Endocrinol Metab 88 2003 3167 3176
74. B.P. Lukert, B.E. Johnson, and R.G. Robinson Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss J Bone Min Res 7 9 1992 1063 1069
75. G.M. Hall, M. Daniels, and D.V. Dolye Effect of hormone replacement therapy on bone mass in rheumatoid arthritis with and without steroids Arthritis Rheum 37 1994 1499 1505
76. Writing Group for the Womens Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women JAMA 282 2002 321 333
77. B. Ettinger, D.M. Black, and B.H. Mitlak Reduction in vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year, randomized clinical trial. Multiple outcome of Raloxifene (MORE) Investigators JAMA 282 1999 637 645
78. J.D. Ringe, and D. Welzel Salmon calcitonin in the therapy of corticoid-induced osteoporosis Eur J Clin Pharmacol 33 1987 35 39
79. J.H. Healey, S.A. Paget, and P. Williams-Russo A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica Calcif Tissue Int 58 1996 73 80
80. A. Kotaniemi, H. Piirainen, and L. Paimela Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? J Rheumatol 23 1996 1875 1879
81. J.D. Adachi, A. Cranney, and C.H. Goldsmith Intermittent cyclic therapy with etidronate in the prevention of corticosteroid-induced bone loss J Rheumatol 21 1994 1922 1926
82. A. Struys, A.A. Snelder, and H. Mulder Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis Am J Med 99 1995 235 242
83. J.D. Adachi, W.G. Bensen, and J. Brown Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis N Engl J Med 337 1997 382 387
84. P. Geusens, J. Dequeker, and J. Vanhoof Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double-blind, randomized placebo-controlled study Ann Rheum Dis 57 1998 724 727
85. E.A. Jenkins, K.E. Walker-Bone, and A. Wood The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate Scand J Rheumatol 28 1999 152 156
86. C. Roux, P. Oriente, and R. Laan Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss J Clin Endocrinol Metab 83 1998 1128 1133
87. J.D. Adachi, C. Roux, and P.I. Pitt A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss J Rheumatol 27 2000 2424 2431
88. K.G. Saag, R. Emkey, and T.J. Schnitzer Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis N Engl J Med 339 5 1998 292 299
89. J.D. Adachi, K.G. Saag, and P.D. Delmas Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids Arthritis Rheum 44 1 2001 202 211
90. P.M. Chavassieux, M.E. Arlot, and J.P. Roux Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies J Bone Miner Res 15 4 2000 754 762
91. S. Wallach, S. Cohen, and D.M. Reid Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy Calcif Tissue Int 67 2000 277 285
92. D.M. Reid, R.A. Hughes, and R.F. Laan Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial J Bone Miner Res 15 2000 1006 1013
93. Y. Boutsen, J. Jamart, and W. Esselinckx Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone J Bone Miner Res 16 2001 104 112
94. Y. Boutsen, J. Jamart, and W. Esselinckx Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial Calcif Tissue Int 61 1997 266 271
95. J.D. Ringe, A. Dorst, and H. Faber Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study Osteoporos Int 14 2003 801 807
96. N.E. Lane, S. Sanchez, and G.W. Modin Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis J Clin Invest 102 1998 1627 1633
97. N.E. Lane, S. Sanchez, and G.W. Modin Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial J Bone Miner Res 15 2000 944 951
98. Q. Rehman, T.F. Lang, and C.D. Arnaud Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis Osteoporos Int 14 2003 77 81
99. W.F. Lems, W.G. Jacobs, and J.W.J. Bijlsma Effect of sodium fluoride in the prevention of corticosteroid-induced osteoporosis Osteoporos Int 7 1997 575 582
100. W.F. Lems, J.W.G. Jacobs, and J.W.J. Bijlsma Is addition of fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis 56 1997 357 363
101. B.L. Riggs, S.F. Hodgson, and W.M. O'Fallon Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis N Engl J Med 322 1990 802 809
102. P.J. Meunier, C. Roux, and E. Seeman The effects of strontium ranelate on the risk of vertebral fractures in women with postmenopausal osteoporosis N Engl J Med 350 2004 459 468